Completed PHASE3 INTERVENTIONAL NCT00043927

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer.

Sponsor: GlaxoSmithKline

Conditions Small Cell Lung Cancer

Interventions etoposide/cisplatin topotecan/cisplatin

Updated 7 times since 2017 Last updated: Aug 20, 2013 Started: Apr 30, 2001 Primary completion: Jan 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Abingdon, United States , Albany, United States , Albuquerque, United States , Apeldoorn, Netherlands , Arnhem, Netherlands , Atlanta, United States , Augusta, United States , Aurora, United States , Banská Bystrica, Slovakia and 147 more locations